

Trimurthi Drugs & Pharmaceuticals Ltd.

Date: 28-01-2013

To
BOMBAY STOCK EXCHANGE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400 001.

Dear Sir,

Sub: Outcome of board meeting held on 28-01-2012.

With reference to the subject cited, this is inform the Exchange that at the Board meeting of M/s. Trimurthi Drugs & Pharmaceuticals Ltd held on Monday, 28-01-2012 at the registered office of the company the following were duly considered and approved by the Board:

1. Un-audited financial results for the quarter ended 31-12-2012. (attached)
2. Limited Review Report for the quarter ended 30-12-2012. (attached)

Thanks & Regards,

Yours Faithfully,
For Trimurthi Drugs & Pharmaceuticals Ltd.,

Arvind Kumar Bhangadia,
Managing Director


Encl: as above

TDPL
TRIMURTHI DRUGS & PHARMACEUTICALS LTD.
 UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED DECEMBER, 2012

29

Particulars	3 Months ended 31-12-2012	Preceeding 3 months ended 30-09-2012	Corresponding 3 months ended 31-12-2011	Year to date figures for the current period ended 31-12-2012	Year to date figures for the current period ended 31-12-2011	Year ended 31-03-2012
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Net Sales / Income from Operations	114.53	140.46	442.68	410.81	895.52	1109.71
2. Other Income	24.10	19.98	23.89	60.05	58.13	73.89
3. Total Income	138.63	160.45	466.57	470.86	953.65	1183.60
4. Expenditure						
a. (Increase)/Decrease in stock in trade and work in Progress	(0.76)	21.80	11.74	11.10	33.94	39.69
b. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil	Nil
c. Purchase of Traded Goods	100.22	101.62	410.23	350.22	801.08	997.46
d. Employees Cost	6.66	4.66	6.56	16.80	19.32	27.41
e. Rent	1.77	1.59	1.68	5.13	5.13	7.08
f. Depreciation	6.91	6.68	8.12	20.15	20.17	26.21
g. Other Expenditure	4.22	5.52	6.00	15.04	16.99	24.39
Total	119.03	141.87	444.33	418.45	896.63	1122.24
5. Interest	0.00	0.00	0.19	0.00	0.69	0.85
6. Exceptional items	Nil	Nil	Nil	Nil	Nil	Nil
7. Profit/ (Loss) from Ordinary activities before tax (3) - (4+5+6)	19.61	18.58	22.05	52.42	56.33	60.51
8. Tax Expense (Including Deferred and Finge Benefit tax)	8.23	4.91	5.30	16.98	15.15	14.10
9. Net Profit/ (Loss) from Ordinary activities after Tax (7-8)	11.38	13.67	16.75	35.44	41.18	46.41
10. Extraorindary Items	Nil	Nil	Nil	Nil	Nil	Nil
11. Net Profit/ (Loss) for the period (9-10)	11.38	13.67	16.75	35.44	41.18	46.41
Paid-up Equity Share Capital (Face Value of						
12. Rs.10/- each)	675.00	675.00	675.00	675.00	675.00	675.00
Reserves excluding revaluation reserves as per						
13. balance sheet of previous accounting year	134.02	134.02	134.02	134.02	134.02	134.02
14. Earnings Per Share (EPS)						
a. Basic and diluted EPS before extraordinary items for the period, for the year to data and for the previous year (not to be annualised)	0.17	0.20	0.25	0.53	0.61	0.69
15. Public Share Holding						
- Number of Shares	2016200	2016200	2016200	2016200	2016200	2016200
- Percentage of shareholding	29.87%	29.87%	29.87%	29.87%	29.87%	29.87%
16. Promoters and promoter group shareholding						
a. Pledged / encumbered						
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
a. Non encumbered						
- No of Equity Shares	4733800	4733800	4733800	4733800	4733800	4733800
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	70.13%	70.13%	70.13%	70.13%	70.13%	70.13%

For Trimurthi Drugs & Pharmaceuticals Ltd.



Managing Director

4-4-231/1/2/ABC, Inderbagh, Sultan Bazar, Hyderabad - 500 095.

Tel : (0) 040 24757370, 66662369 Fax : 040 24757370 e-mail : info@trimurthidrugs.com

Segment Reporting

Particulars	Quarters ended			Nine Months ended		Year ended
	31/12/2012	30/09/2012	31/12/2011	31/12/2012	31/12/2011	31/03/2012
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment Revenue						
a. Pharma Business	118.75	143.78	443.77	418.63	900.54	1117.10
b. Financial Services	16.59	19.66	15.95	51.94	46.26	59.65
c. Investments	25.03	25.80	8.20	50.83	58.74	6.85
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
Total	160.37	189.24	467.92	521.40	1005.54	1183.60
2. Segment Profits						
a. Pharma Business	1.53	3.29	1.23	4.99	8.44	1.40
b. Financial Services	17.10	15.97	13.97	47.14	41.04	52.27
c. Investment in shares	0.29	0.00	6.85	0.29	6.85	6.85
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00	0.00
Total	18.92	19.26	22.05	52.42	56.33	60.52
3. Capital Employed						
a. Pharma Business	364.36	276.98	285.83	364.36	285.83	268.32
b. Financial Services	567.23	535.49	415.50	567.23	415.50	410.17
c. Investments	8.00	29.74	50.54	8.00	50.54	50.54
d. Trading in Shares	0.00	0.00	Nil	0.00	Nil	Nil
Total	939.59	842.21	751.87	939.59	751.87	729.02

Notes:

1. The above results have been taken on record by the board of directors of the company at their meeting held on 28/01/2013.
2. The financial results for the quarter ended 31-12-2012 have been reviewed by the statutory auditors in pursuance of listing agreement.
3. In segment reporting common assets that are used interchangeable not allocated to the individual segment above.
4. The status of investor grievances for the quarter ended 28/01/2013:
 - a. pending at the beginning - Nil
 - b. received - 1
 - c. settled - 1
 - d. pending at the end - Nil

Place : Hyderabad,
 Date : 28/01/2013.

For Trimurthi D^rugs & P^harmaceuticals L^{td}
 For Trimurthi Drugs & P^harmaceuticals L^{td}
 [Signature]
 Managing Director